开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：纳米载体;中药药理 经验分享：今天接收啦，发个时间给大家看一下，总共4个月左右 16 April 2023 Submission created 19 April 2023 Submission submitted + Editorial checks 1 May 2023 Editorial checks completed moved to Compliance checks 5 May 2023 Peer review selection 17 May 2023 Peer review invitations sent 31 May 2023 First peer reviewer allocated 1 June 2023 Two or more peer reviewers allocated 1 June 2023 First report returned 14 June 2023 Second or more peer reviewer reports returned 15 June 2023 Report sent to the Editor-in-Chief 17 June 2023 Report: revise with changes 29 June 2023 Resubmission pending 19 July 2023 Resubmitted manuscript received 27 July 2023 Processing revised manuscript 4 August 2023 Sent to Editor-in-Chief for acceptance or rejection 4 August 2023 Peer reviewer(s) second round 12 August 2023 Peer reviewer(s) second round completed 12 August 2023 Invoice to follow for article processing charge subject to final decision 14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209502, encodeId=4ba52209502e3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：单体中药 经验分享：Submission 29 December 2023 Submission created 1 February 2024 Awaiting author/editor confirmation 12 February 2024 Revised submission received 12 February 2024 Awaiting re-submission 12 February 2024 Revised submission received 13 February 2024 Awaiting re-submission 13 February 2024 Revised submission received 13 February 2024 Editorial checks completed moved to Compliance checks 2 Peer Review 23 February 2024 Peer review selection 2 March 2024 Peer review invitations sent 16 March 2024 First peer reviewer allocated 31 March 2024 First report returned 31 March 2024 Second or more peer reviewer reports returned 3 Editorial decision - revisions 12 April 2024 Report sent to the Editor-in-Chief 22 April 2024 Report: revise with changes 27 April 2024 Resubmission pending 16 May 2024 Resubmitted manuscript received 21 May 2024 Processing revised manuscript 23 May 2024 Sent to Editor-in-Chief for acceptance or rejection 20 May 2024 Query regarding revised manuscript 4 Invoicing 1 June 2024 Invoice to follow for article processing charge subject to final decision 4 June 2024 Accepted for publication, invoice sent 5 Production 10 June 2024 Payment has been received 11 June 2024 Manuscript sent to typesetter for pre-edit. No action required from the author 12 June 2024 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 12 June 2024 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 12 June 2024 Author has returned corrections, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83561965054, createdName=1e147e00m93(暂无匿称), createdTime=Wed Jun 12 14:04:42 CST 2024, time=2024-06-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2151252, encodeId=147f215125205, content=邮件已经确认付费，状态依然是1DA - WAITING FOR THIRD PARTY BILLING INFORMATION，请问需要什么处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efde6513305, createdName=ms9000000076911288, createdTime=Fri Aug 04 11:48:25 CST 2023, time=2023-08-04, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2169183, encodeId=81632169183a3, content=我想知道2A最久可以持续多久，我已经持续17天了，还在邀请审稿人，捉急毕业啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2696410801, createdName=ms6000001755760996, createdTime=Fri Nov 17 21:33:55 CST 2023, time=2023-11-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省)]

2024-08-31 汉库克来自湖北省

偏重的研究方向：治疗;药物;药物治疗
经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估

16 0

[GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：纳米载体;中药药理 经验分享：今天接收啦，发个时间给大家看一下，总共4个月左右 16 April 2023 Submission created 19 April 2023 Submission submitted + Editorial checks 1 May 2023 Editorial checks completed moved to Compliance checks 5 May 2023 Peer review selection 17 May 2023 Peer review invitations sent 31 May 2023 First peer reviewer allocated 1 June 2023 Two or more peer reviewers allocated 1 June 2023 First report returned 14 June 2023 Second or more peer reviewer reports returned 15 June 2023 Report sent to the Editor-in-Chief 17 June 2023 Report: revise with changes 29 June 2023 Resubmission pending 19 July 2023 Resubmitted manuscript received 27 July 2023 Processing revised manuscript 4 August 2023 Sent to Editor-in-Chief for acceptance or rejection 4 August 2023 Peer reviewer(s) second round 12 August 2023 Peer reviewer(s) second round completed 12 August 2023 Invoice to follow for article processing charge subject to final decision 14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209502, encodeId=4ba52209502e3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：单体中药 经验分享：Submission 29 December 2023 Submission created 1 February 2024 Awaiting author/editor confirmation 12 February 2024 Revised submission received 12 February 2024 Awaiting re-submission 12 February 2024 Revised submission received 13 February 2024 Awaiting re-submission 13 February 2024 Revised submission received 13 February 2024 Editorial checks completed moved to Compliance checks 2 Peer Review 23 February 2024 Peer review selection 2 March 2024 Peer review invitations sent 16 March 2024 First peer reviewer allocated 31 March 2024 First report returned 31 March 2024 Second or more peer reviewer reports returned 3 Editorial decision - revisions 12 April 2024 Report sent to the Editor-in-Chief 22 April 2024 Report: revise with changes 27 April 2024 Resubmission pending 16 May 2024 Resubmitted manuscript received 21 May 2024 Processing revised manuscript 23 May 2024 Sent to Editor-in-Chief for acceptance or rejection 20 May 2024 Query regarding revised manuscript 4 Invoicing 1 June 2024 Invoice to follow for article processing charge subject to final decision 4 June 2024 Accepted for publication, invoice sent 5 Production 10 June 2024 Payment has been received 11 June 2024 Manuscript sent to typesetter for pre-edit. No action required from the author 12 June 2024 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 12 June 2024 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 12 June 2024 Author has returned corrections, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83561965054, createdName=1e147e00m93(暂无匿称), createdTime=Wed Jun 12 14:04:42 CST 2024, time=2024-06-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2151252, encodeId=147f215125205, content=邮件已经确认付费，状态依然是1DA - WAITING FOR THIRD PARTY BILLING INFORMATION，请问需要什么处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efde6513305, createdName=ms9000000076911288, createdTime=Fri Aug 04 11:48:25 CST 2023, time=2023-08-04, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2169183, encodeId=81632169183a3, content=我想知道2A最久可以持续多久，我已经持续17天了，还在邀请审稿人，捉急毕业啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2696410801, createdName=ms6000001755760996, createdTime=Fri Nov 17 21:33:55 CST 2023, time=2023-11-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省)]

2024-08-17 ms9000001638905587 来自吉林省

请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，

36 0

[GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：纳米载体;中药药理 经验分享：今天接收啦，发个时间给大家看一下，总共4个月左右 16 April 2023 Submission created 19 April 2023 Submission submitted + Editorial checks 1 May 2023 Editorial checks completed moved to Compliance checks 5 May 2023 Peer review selection 17 May 2023 Peer review invitations sent 31 May 2023 First peer reviewer allocated 1 June 2023 Two or more peer reviewers allocated 1 June 2023 First report returned 14 June 2023 Second or more peer reviewer reports returned 15 June 2023 Report sent to the Editor-in-Chief 17 June 2023 Report: revise with changes 29 June 2023 Resubmission pending 19 July 2023 Resubmitted manuscript received 27 July 2023 Processing revised manuscript 4 August 2023 Sent to Editor-in-Chief for acceptance or rejection 4 August 2023 Peer reviewer(s) second round 12 August 2023 Peer reviewer(s) second round completed 12 August 2023 Invoice to follow for article processing charge subject to final decision 14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209502, encodeId=4ba52209502e3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：单体中药 经验分享：Submission 29 December 2023 Submission created 1 February 2024 Awaiting author/editor confirmation 12 February 2024 Revised submission received 12 February 2024 Awaiting re-submission 12 February 2024 Revised submission received 13 February 2024 Awaiting re-submission 13 February 2024 Revised submission received 13 February 2024 Editorial checks completed moved to Compliance checks 2 Peer Review 23 February 2024 Peer review selection 2 March 2024 Peer review invitations sent 16 March 2024 First peer reviewer allocated 31 March 2024 First report returned 31 March 2024 Second or more peer reviewer reports returned 3 Editorial decision - revisions 12 April 2024 Report sent to the Editor-in-Chief 22 April 2024 Report: revise with changes 27 April 2024 Resubmission pending 16 May 2024 Resubmitted manuscript received 21 May 2024 Processing revised manuscript 23 May 2024 Sent to Editor-in-Chief for acceptance or rejection 20 May 2024 Query regarding revised manuscript 4 Invoicing 1 June 2024 Invoice to follow for article processing charge subject to final decision 4 June 2024 Accepted for publication, invoice sent 5 Production 10 June 2024 Payment has been received 11 June 2024 Manuscript sent to typesetter for pre-edit. No action required from the author 12 June 2024 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 12 June 2024 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 12 June 2024 Author has returned corrections, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83561965054, createdName=1e147e00m93(暂无匿称), createdTime=Wed Jun 12 14:04:42 CST 2024, time=2024-06-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2151252, encodeId=147f215125205, content=邮件已经确认付费，状态依然是1DA - WAITING FOR THIRD PARTY BILLING INFORMATION，请问需要什么处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efde6513305, createdName=ms9000000076911288, createdTime=Fri Aug 04 11:48:25 CST 2023, time=2023-08-04, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2169183, encodeId=81632169183a3, content=我想知道2A最久可以持续多久，我已经持续17天了，还在邀请审稿人，捉急毕业啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2696410801, createdName=ms6000001755760996, createdTime=Fri Nov 17 21:33:55 CST 2023, time=2023-11-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省)]

2024-08-16 ms5000001216482403 来自山东省

审稿速度:6.0 | 投稿命中率:50.0
经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误

37 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：纳米载体;中药药理 经验分享：今天接收啦，发个时间给大家看一下，总共4个月左右 16 April 2023 Submission created 19 April 2023 Submission submitted + Editorial checks 1 May 2023 Editorial checks completed moved to Compliance checks 5 May 2023 Peer review selection 17 May 2023 Peer review invitations sent 31 May 2023 First peer reviewer allocated 1 June 2023 Two or more peer reviewers allocated 1 June 2023 First report returned 14 June 2023 Second or more peer reviewer reports returned 15 June 2023 Report sent to the Editor-in-Chief 17 June 2023 Report: revise with changes 29 June 2023 Resubmission pending 19 July 2023 Resubmitted manuscript received 27 July 2023 Processing revised manuscript 4 August 2023 Sent to Editor-in-Chief for acceptance or rejection 4 August 2023 Peer reviewer(s) second round 12 August 2023 Peer reviewer(s) second round completed 12 August 2023 Invoice to follow for article processing charge subject to final decision 14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209502, encodeId=4ba52209502e3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：单体中药 经验分享：Submission 29 December 2023 Submission created 1 February 2024 Awaiting author/editor confirmation 12 February 2024 Revised submission received 12 February 2024 Awaiting re-submission 12 February 2024 Revised submission received 13 February 2024 Awaiting re-submission 13 February 2024 Revised submission received 13 February 2024 Editorial checks completed moved to Compliance checks 2 Peer Review 23 February 2024 Peer review selection 2 March 2024 Peer review invitations sent 16 March 2024 First peer reviewer allocated 31 March 2024 First report returned 31 March 2024 Second or more peer reviewer reports returned 3 Editorial decision - revisions 12 April 2024 Report sent to the Editor-in-Chief 22 April 2024 Report: revise with changes 27 April 2024 Resubmission pending 16 May 2024 Resubmitted manuscript received 21 May 2024 Processing revised manuscript 23 May 2024 Sent to Editor-in-Chief for acceptance or rejection 20 May 2024 Query regarding revised manuscript 4 Invoicing 1 June 2024 Invoice to follow for article processing charge subject to final decision 4 June 2024 Accepted for publication, invoice sent 5 Production 10 June 2024 Payment has been received 11 June 2024 Manuscript sent to typesetter for pre-edit. No action required from the author 12 June 2024 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 12 June 2024 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 12 June 2024 Author has returned corrections, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83561965054, createdName=1e147e00m93(暂无匿称), createdTime=Wed Jun 12 14:04:42 CST 2024, time=2024-06-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2151252, encodeId=147f215125205, content=邮件已经确认付费，状态依然是1DA - WAITING FOR THIRD PARTY BILLING INFORMATION，请问需要什么处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efde6513305, createdName=ms9000000076911288, createdTime=Fri Aug 04 11:48:25 CST 2023, time=2023-08-04, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2169183, encodeId=81632169183a3, content=我想知道2A最久可以持续多久，我已经持续17天了，还在邀请审稿人，捉急毕业啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2696410801, createdName=ms6000001755760996, createdTime=Fri Nov 17 21:33:55 CST 2023, time=2023-11-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省)]

2024-07-25 148817e2m02暂无昵称来自江苏省

偏重的研究方向：药物;药物治疗
经验分享：大家好，请问大家1A1状态一般持续多久呀

43 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：纳米载体;中药药理 经验分享：今天接收啦，发个时间给大家看一下，总共4个月左右 16 April 2023 Submission created 19 April 2023 Submission submitted + Editorial checks 1 May 2023 Editorial checks completed moved to Compliance checks 5 May 2023 Peer review selection 17 May 2023 Peer review invitations sent 31 May 2023 First peer reviewer allocated 1 June 2023 Two or more peer reviewers allocated 1 June 2023 First report returned 14 June 2023 Second or more peer reviewer reports returned 15 June 2023 Report sent to the Editor-in-Chief 17 June 2023 Report: revise with changes 29 June 2023 Resubmission pending 19 July 2023 Resubmitted manuscript received 27 July 2023 Processing revised manuscript 4 August 2023 Sent to Editor-in-Chief for acceptance or rejection 4 August 2023 Peer reviewer(s) second round 12 August 2023 Peer reviewer(s) second round completed 12 August 2023 Invoice to follow for article processing charge subject to final decision 14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209502, encodeId=4ba52209502e3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：单体中药 经验分享：Submission 29 December 2023 Submission created 1 February 2024 Awaiting author/editor confirmation 12 February 2024 Revised submission received 12 February 2024 Awaiting re-submission 12 February 2024 Revised submission received 13 February 2024 Awaiting re-submission 13 February 2024 Revised submission received 13 February 2024 Editorial checks completed moved to Compliance checks 2 Peer Review 23 February 2024 Peer review selection 2 March 2024 Peer review invitations sent 16 March 2024 First peer reviewer allocated 31 March 2024 First report returned 31 March 2024 Second or more peer reviewer reports returned 3 Editorial decision - revisions 12 April 2024 Report sent to the Editor-in-Chief 22 April 2024 Report: revise with changes 27 April 2024 Resubmission pending 16 May 2024 Resubmitted manuscript received 21 May 2024 Processing revised manuscript 23 May 2024 Sent to Editor-in-Chief for acceptance or rejection 20 May 2024 Query regarding revised manuscript 4 Invoicing 1 June 2024 Invoice to follow for article processing charge subject to final decision 4 June 2024 Accepted for publication, invoice sent 5 Production 10 June 2024 Payment has been received 11 June 2024 Manuscript sent to typesetter for pre-edit. No action required from the author 12 June 2024 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 12 June 2024 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 12 June 2024 Author has returned corrections, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83561965054, createdName=1e147e00m93(暂无匿称), createdTime=Wed Jun 12 14:04:42 CST 2024, time=2024-06-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2151252, encodeId=147f215125205, content=邮件已经确认付费，状态依然是1DA - WAITING FOR THIRD PARTY BILLING INFORMATION，请问需要什么处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efde6513305, createdName=ms9000000076911288, createdTime=Fri Aug 04 11:48:25 CST 2023, time=2023-08-04, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2169183, encodeId=81632169183a3, content=我想知道2A最久可以持续多久，我已经持续17天了，还在邀请审稿人，捉急毕业啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2696410801, createdName=ms6000001755760996, createdTime=Fri Nov 17 21:33:55 CST 2023, time=2023-11-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省)]

2024-06-19 ms5000000946930121 来自天津

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：药理
经验分享：
3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程
6 March 2024

Submission created

20 March 2024

Compliance checks completed

21 March 2024

Awaiting evaluation

25 March 2024

Compliance checks completed

27 March 2024

Awaiting evaluation

28 March 2024

Compliance checks completed

2 April 2024

Awaiting re-submission

2 April 2024

Revised submission received

3 April 2024

Editorial checks completed moved to Compliance checks

20 March 2024

Peer review selection

9 April 2024

Peer review invitations sent

13 April 2024

First peer reviewer allocated

26 April 2024

First report returned

3 May 2024

Second or more peer reviewer reports returned

Editorial decision - revisions
3 May 2024

Report sent to the Editor-in-Chief

4 May 2024

Report: revise with changes

14 May 2024

Resubmission pending

1 June 2024

Resubmitted manuscript received

5 June 2024

Processing revised manuscript

7 June 2024

Sent to Editor-in-Chief for acceptance or rejection

5 June 2024

Query regarding revised manuscript

Invoicing
8 June 2024

Invoice to follow for article processing charge subject to final decision

10 June 2024

Accepted for publication, invoice sent

65 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：纳米载体;中药药理 经验分享：今天接收啦，发个时间给大家看一下，总共4个月左右 16 April 2023 Submission created 19 April 2023 Submission submitted + Editorial checks 1 May 2023 Editorial checks completed moved to Compliance checks 5 May 2023 Peer review selection 17 May 2023 Peer review invitations sent 31 May 2023 First peer reviewer allocated 1 June 2023 Two or more peer reviewers allocated 1 June 2023 First report returned 14 June 2023 Second or more peer reviewer reports returned 15 June 2023 Report sent to the Editor-in-Chief 17 June 2023 Report: revise with changes 29 June 2023 Resubmission pending 19 July 2023 Resubmitted manuscript received 27 July 2023 Processing revised manuscript 4 August 2023 Sent to Editor-in-Chief for acceptance or rejection 4 August 2023 Peer reviewer(s) second round 12 August 2023 Peer reviewer(s) second round completed 12 August 2023 Invoice to follow for article processing charge subject to final decision 14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209502, encodeId=4ba52209502e3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：单体中药 经验分享：Submission 29 December 2023 Submission created 1 February 2024 Awaiting author/editor confirmation 12 February 2024 Revised submission received 12 February 2024 Awaiting re-submission 12 February 2024 Revised submission received 13 February 2024 Awaiting re-submission 13 February 2024 Revised submission received 13 February 2024 Editorial checks completed moved to Compliance checks 2 Peer Review 23 February 2024 Peer review selection 2 March 2024 Peer review invitations sent 16 March 2024 First peer reviewer allocated 31 March 2024 First report returned 31 March 2024 Second or more peer reviewer reports returned 3 Editorial decision - revisions 12 April 2024 Report sent to the Editor-in-Chief 22 April 2024 Report: revise with changes 27 April 2024 Resubmission pending 16 May 2024 Resubmitted manuscript received 21 May 2024 Processing revised manuscript 23 May 2024 Sent to Editor-in-Chief for acceptance or rejection 20 May 2024 Query regarding revised manuscript 4 Invoicing 1 June 2024 Invoice to follow for article processing charge subject to final decision 4 June 2024 Accepted for publication, invoice sent 5 Production 10 June 2024 Payment has been received 11 June 2024 Manuscript sent to typesetter for pre-edit. No action required from the author 12 June 2024 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 12 June 2024 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 12 June 2024 Author has returned corrections, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83561965054, createdName=1e147e00m93(暂无匿称), createdTime=Wed Jun 12 14:04:42 CST 2024, time=2024-06-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2151252, encodeId=147f215125205, content=邮件已经确认付费，状态依然是1DA - WAITING FOR THIRD PARTY BILLING INFORMATION，请问需要什么处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efde6513305, createdName=ms9000000076911288, createdTime=Fri Aug 04 11:48:25 CST 2023, time=2023-08-04, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2169183, encodeId=81632169183a3, content=我想知道2A最久可以持续多久，我已经持续17天了，还在邀请审稿人，捉急毕业啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2696410801, createdName=ms6000001755760996, createdTime=Fri Nov 17 21:33:55 CST 2023, time=2023-11-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省)]

2023-08-14 ms8000001566471502 来自山东省

审稿速度:6.0 | 投稿命中率:75.0
偏重的研究方向：纳米载体;中药药理
经验分享：今天接收啦，发个时间给大家看一下，总共4个月左右
16 April 2023 Submission created
19 April 2023 Submission submitted + Editorial checks
1 May 2023 Editorial checks completed moved to Compliance checks
5 May 2023 Peer review selection
17 May 2023 Peer review invitations sent
31 May 2023 First peer reviewer allocated
1 June 2023 Two or more peer reviewers allocated
1 June 2023 First report returned
14 June 2023 Second or more peer reviewer reports returned
15 June 2023 Report sent to the Editor-in-Chief
17 June 2023 Report: revise with changes
29 June 2023 Resubmission pending
19 July 2023 Resubmitted manuscript received
27 July 2023 Processing revised manuscript
4 August 2023 Sent to Editor-in-Chief for acceptance or rejection
4 August 2023 Peer reviewer(s) second round
12 August 2023 Peer reviewer(s) second round completed
12 August 2023 Invoice to follow for article processing charge subject to final decision
14 August 2023 Accepted for publication, invoice sent

130 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：纳米载体;中药药理 经验分享：今天接收啦，发个时间给大家看一下，总共4个月左右 16 April 2023 Submission created 19 April 2023 Submission submitted + Editorial checks 1 May 2023 Editorial checks completed moved to Compliance checks 5 May 2023 Peer review selection 17 May 2023 Peer review invitations sent 31 May 2023 First peer reviewer allocated 1 June 2023 Two or more peer reviewers allocated 1 June 2023 First report returned 14 June 2023 Second or more peer reviewer reports returned 15 June 2023 Report sent to the Editor-in-Chief 17 June 2023 Report: revise with changes 29 June 2023 Resubmission pending 19 July 2023 Resubmitted manuscript received 27 July 2023 Processing revised manuscript 4 August 2023 Sent to Editor-in-Chief for acceptance or rejection 4 August 2023 Peer reviewer(s) second round 12 August 2023 Peer reviewer(s) second round completed 12 August 2023 Invoice to follow for article processing charge subject to final decision 14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209502, encodeId=4ba52209502e3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：单体中药 经验分享：Submission 29 December 2023 Submission created 1 February 2024 Awaiting author/editor confirmation 12 February 2024 Revised submission received 12 February 2024 Awaiting re-submission 12 February 2024 Revised submission received 13 February 2024 Awaiting re-submission 13 February 2024 Revised submission received 13 February 2024 Editorial checks completed moved to Compliance checks 2 Peer Review 23 February 2024 Peer review selection 2 March 2024 Peer review invitations sent 16 March 2024 First peer reviewer allocated 31 March 2024 First report returned 31 March 2024 Second or more peer reviewer reports returned 3 Editorial decision - revisions 12 April 2024 Report sent to the Editor-in-Chief 22 April 2024 Report: revise with changes 27 April 2024 Resubmission pending 16 May 2024 Resubmitted manuscript received 21 May 2024 Processing revised manuscript 23 May 2024 Sent to Editor-in-Chief for acceptance or rejection 20 May 2024 Query regarding revised manuscript 4 Invoicing 1 June 2024 Invoice to follow for article processing charge subject to final decision 4 June 2024 Accepted for publication, invoice sent 5 Production 10 June 2024 Payment has been received 11 June 2024 Manuscript sent to typesetter for pre-edit. No action required from the author 12 June 2024 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 12 June 2024 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 12 June 2024 Author has returned corrections, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83561965054, createdName=1e147e00m93(暂无匿称), createdTime=Wed Jun 12 14:04:42 CST 2024, time=2024-06-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2151252, encodeId=147f215125205, content=邮件已经确认付费，状态依然是1DA - WAITING FOR THIRD PARTY BILLING INFORMATION，请问需要什么处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efde6513305, createdName=ms9000000076911288, createdTime=Fri Aug 04 11:48:25 CST 2023, time=2023-08-04, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2169183, encodeId=81632169183a3, content=我想知道2A最久可以持续多久，我已经持续17天了，还在邀请审稿人，捉急毕业啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2696410801, createdName=ms6000001755760996, createdTime=Fri Nov 17 21:33:55 CST 2023, time=2023-11-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省)]

2024-06-12 1e147e00m93(暂无匿称) 来自河南省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：单体中药
经验分享：Submission
29 December 2023

Submission created

1 February 2024

Awaiting author/editor confirmation

12 February 2024

Revised submission received

12 February 2024

Awaiting re-submission

12 February 2024

Revised submission received

13 February 2024

Awaiting re-submission

13 February 2024

Revised submission received

13 February 2024

Editorial checks completed moved to Compliance checks

2
Peer Review
23 February 2024

Peer review selection

2 March 2024

Peer review invitations sent

16 March 2024

First peer reviewer allocated

31 March 2024

First report returned

31 March 2024

Second or more peer reviewer reports returned

3
Editorial decision - revisions
12 April 2024

Report sent to the Editor-in-Chief

22 April 2024

Report: revise with changes

27 April 2024

Resubmission pending

16 May 2024

Resubmitted manuscript received

21 May 2024

Processing revised manuscript

23 May 2024

Sent to Editor-in-Chief for acceptance or rejection

20 May 2024

Query regarding revised manuscript

4
Invoicing
1 June 2024

Invoice to follow for article processing charge subject to final decision

4 June 2024

Accepted for publication, invoice sent

5
Production
10 June 2024

Payment has been received

11 June 2024

Manuscript sent to typesetter for pre-edit. No action required from the author

12 June 2024

Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author

12 June 2024

Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team

12 June 2024

Author has returned corrections

58 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：纳米载体;中药药理 经验分享：今天接收啦，发个时间给大家看一下，总共4个月左右 16 April 2023 Submission created 19 April 2023 Submission submitted + Editorial checks 1 May 2023 Editorial checks completed moved to Compliance checks 5 May 2023 Peer review selection 17 May 2023 Peer review invitations sent 31 May 2023 First peer reviewer allocated 1 June 2023 Two or more peer reviewers allocated 1 June 2023 First report returned 14 June 2023 Second or more peer reviewer reports returned 15 June 2023 Report sent to the Editor-in-Chief 17 June 2023 Report: revise with changes 29 June 2023 Resubmission pending 19 July 2023 Resubmitted manuscript received 27 July 2023 Processing revised manuscript 4 August 2023 Sent to Editor-in-Chief for acceptance or rejection 4 August 2023 Peer reviewer(s) second round 12 August 2023 Peer reviewer(s) second round completed 12 August 2023 Invoice to follow for article processing charge subject to final decision 14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209502, encodeId=4ba52209502e3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：单体中药 经验分享：Submission 29 December 2023 Submission created 1 February 2024 Awaiting author/editor confirmation 12 February 2024 Revised submission received 12 February 2024 Awaiting re-submission 12 February 2024 Revised submission received 13 February 2024 Awaiting re-submission 13 February 2024 Revised submission received 13 February 2024 Editorial checks completed moved to Compliance checks 2 Peer Review 23 February 2024 Peer review selection 2 March 2024 Peer review invitations sent 16 March 2024 First peer reviewer allocated 31 March 2024 First report returned 31 March 2024 Second or more peer reviewer reports returned 3 Editorial decision - revisions 12 April 2024 Report sent to the Editor-in-Chief 22 April 2024 Report: revise with changes 27 April 2024 Resubmission pending 16 May 2024 Resubmitted manuscript received 21 May 2024 Processing revised manuscript 23 May 2024 Sent to Editor-in-Chief for acceptance or rejection 20 May 2024 Query regarding revised manuscript 4 Invoicing 1 June 2024 Invoice to follow for article processing charge subject to final decision 4 June 2024 Accepted for publication, invoice sent 5 Production 10 June 2024 Payment has been received 11 June 2024 Manuscript sent to typesetter for pre-edit. No action required from the author 12 June 2024 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 12 June 2024 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 12 June 2024 Author has returned corrections, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83561965054, createdName=1e147e00m93(暂无匿称), createdTime=Wed Jun 12 14:04:42 CST 2024, time=2024-06-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2151252, encodeId=147f215125205, content=邮件已经确认付费，状态依然是1DA - WAITING FOR THIRD PARTY BILLING INFORMATION，请问需要什么处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efde6513305, createdName=ms9000000076911288, createdTime=Fri Aug 04 11:48:25 CST 2023, time=2023-08-04, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2169183, encodeId=81632169183a3, content=我想知道2A最久可以持续多久，我已经持续17天了，还在邀请审稿人，捉急毕业啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2696410801, createdName=ms6000001755760996, createdTime=Fri Nov 17 21:33:55 CST 2023, time=2023-11-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省)]

2023-08-04 ms9000000076911288 来自浙江省

邮件已经确认付费，状态依然是1DA - WAITING FOR THIRD PARTY BILLING INFORMATION，请问需要什么处理吗？

126 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：纳米载体;中药药理 经验分享：今天接收啦，发个时间给大家看一下，总共4个月左右 16 April 2023 Submission created 19 April 2023 Submission submitted + Editorial checks 1 May 2023 Editorial checks completed moved to Compliance checks 5 May 2023 Peer review selection 17 May 2023 Peer review invitations sent 31 May 2023 First peer reviewer allocated 1 June 2023 Two or more peer reviewers allocated 1 June 2023 First report returned 14 June 2023 Second or more peer reviewer reports returned 15 June 2023 Report sent to the Editor-in-Chief 17 June 2023 Report: revise with changes 29 June 2023 Resubmission pending 19 July 2023 Resubmitted manuscript received 27 July 2023 Processing revised manuscript 4 August 2023 Sent to Editor-in-Chief for acceptance or rejection 4 August 2023 Peer reviewer(s) second round 12 August 2023 Peer reviewer(s) second round completed 12 August 2023 Invoice to follow for article processing charge subject to final decision 14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209502, encodeId=4ba52209502e3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：单体中药 经验分享：Submission 29 December 2023 Submission created 1 February 2024 Awaiting author/editor confirmation 12 February 2024 Revised submission received 12 February 2024 Awaiting re-submission 12 February 2024 Revised submission received 13 February 2024 Awaiting re-submission 13 February 2024 Revised submission received 13 February 2024 Editorial checks completed moved to Compliance checks 2 Peer Review 23 February 2024 Peer review selection 2 March 2024 Peer review invitations sent 16 March 2024 First peer reviewer allocated 31 March 2024 First report returned 31 March 2024 Second or more peer reviewer reports returned 3 Editorial decision - revisions 12 April 2024 Report sent to the Editor-in-Chief 22 April 2024 Report: revise with changes 27 April 2024 Resubmission pending 16 May 2024 Resubmitted manuscript received 21 May 2024 Processing revised manuscript 23 May 2024 Sent to Editor-in-Chief for acceptance or rejection 20 May 2024 Query regarding revised manuscript 4 Invoicing 1 June 2024 Invoice to follow for article processing charge subject to final decision 4 June 2024 Accepted for publication, invoice sent 5 Production 10 June 2024 Payment has been received 11 June 2024 Manuscript sent to typesetter for pre-edit. No action required from the author 12 June 2024 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 12 June 2024 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 12 June 2024 Author has returned corrections, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83561965054, createdName=1e147e00m93(暂无匿称), createdTime=Wed Jun 12 14:04:42 CST 2024, time=2024-06-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2151252, encodeId=147f215125205, content=邮件已经确认付费，状态依然是1DA - WAITING FOR THIRD PARTY BILLING INFORMATION，请问需要什么处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efde6513305, createdName=ms9000000076911288, createdTime=Fri Aug 04 11:48:25 CST 2023, time=2023-08-04, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2169183, encodeId=81632169183a3, content=我想知道2A最久可以持续多久，我已经持续17天了，还在邀请审稿人，捉急毕业啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2696410801, createdName=ms6000001755760996, createdTime=Fri Nov 17 21:33:55 CST 2023, time=2023-11-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省)]

2023-11-17 ms6000001755760996 来自吉林省

我想知道2A最久可以持续多久，我已经持续17天了，还在邀请审稿人，捉急毕业啊

136 0

[GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：纳米载体;中药药理 经验分享：今天接收啦，发个时间给大家看一下，总共4个月左右 16 April 2023 Submission created 19 April 2023 Submission submitted + Editorial checks 1 May 2023 Editorial checks completed moved to Compliance checks 5 May 2023 Peer review selection 17 May 2023 Peer review invitations sent 31 May 2023 First peer reviewer allocated 1 June 2023 Two or more peer reviewers allocated 1 June 2023 First report returned 14 June 2023 Second or more peer reviewer reports returned 15 June 2023 Report sent to the Editor-in-Chief 17 June 2023 Report: revise with changes 29 June 2023 Resubmission pending 19 July 2023 Resubmitted manuscript received 27 July 2023 Processing revised manuscript 4 August 2023 Sent to Editor-in-Chief for acceptance or rejection 4 August 2023 Peer reviewer(s) second round 12 August 2023 Peer reviewer(s) second round completed 12 August 2023 Invoice to follow for article processing charge subject to final decision 14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209502, encodeId=4ba52209502e3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：单体中药 经验分享：Submission 29 December 2023 Submission created 1 February 2024 Awaiting author/editor confirmation 12 February 2024 Revised submission received 12 February 2024 Awaiting re-submission 12 February 2024 Revised submission received 13 February 2024 Awaiting re-submission 13 February 2024 Revised submission received 13 February 2024 Editorial checks completed moved to Compliance checks 2 Peer Review 23 February 2024 Peer review selection 2 March 2024 Peer review invitations sent 16 March 2024 First peer reviewer allocated 31 March 2024 First report returned 31 March 2024 Second or more peer reviewer reports returned 3 Editorial decision - revisions 12 April 2024 Report sent to the Editor-in-Chief 22 April 2024 Report: revise with changes 27 April 2024 Resubmission pending 16 May 2024 Resubmitted manuscript received 21 May 2024 Processing revised manuscript 23 May 2024 Sent to Editor-in-Chief for acceptance or rejection 20 May 2024 Query regarding revised manuscript 4 Invoicing 1 June 2024 Invoice to follow for article processing charge subject to final decision 4 June 2024 Accepted for publication, invoice sent 5 Production 10 June 2024 Payment has been received 11 June 2024 Manuscript sent to typesetter for pre-edit. No action required from the author 12 June 2024 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 12 June 2024 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 12 June 2024 Author has returned corrections, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83561965054, createdName=1e147e00m93(暂无匿称), createdTime=Wed Jun 12 14:04:42 CST 2024, time=2024-06-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2151252, encodeId=147f215125205, content=邮件已经确认付费，状态依然是1DA - WAITING FOR THIRD PARTY BILLING INFORMATION，请问需要什么处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efde6513305, createdName=ms9000000076911288, createdTime=Fri Aug 04 11:48:25 CST 2023, time=2023-08-04, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2169183, encodeId=81632169183a3, content=我想知道2A最久可以持续多久，我已经持续17天了，还在邀请审稿人，捉急毕业啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2696410801, createdName=ms6000001755760996, createdTime=Fri Nov 17 21:33:55 CST 2023, time=2023-11-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省)]

2023-09-20 41982559 来自广东省

偏重的研究方向：药理
经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。

150 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务